ramosetron group (group R	ramosetron plus dexamethasone group (group RD)	moderate to severe nausea	1269	1478	The number of patients with moderate to severe nausea (20 vs. 10, P = 0.029), and overall incidence of vomiting (13 vs. 5, P = 0.037) were significantly lower in the group RD than in the group R, respectively.
ramosetron group (group R	ramosetron plus dexamethasone group (group RD)	moderate to severe nausea	13062	13286	Although the median of the highest VRS scores of nausea intensity during study period was similar between the groups, the number of patients with moderate to severe nausea was significantly lower in the RD group (P = 0.029).
ramosetron group (group R	ramosetron plus dexamethasone group (group RD)	The overall incidence of vomiting	1269	1478	The number of patients with moderate to severe nausea (20 vs. 10, P = 0.029), and overall incidence of vomiting (13 vs. 5, P = 0.037) were significantly lower in the group RD than in the group R, respectively.
ramosetron group (group R	ramosetron plus dexamethasone group (group RD)	The overall incidence of vomiting	13356	13471	The overall incidence of vomiting was significantly lower in the group RD than in the group R (P = 0.037; Table 2).
